Category: ABBV-951

AbbVie files continuous Parkinson’s therapy ABBV-951 in US

May 23, 2022 Auto Bot 0

AbbVie has filed for approval of its therapy for Parkinson’s disease, ABBV-951, which promises continuous control of symptoms and would be an alternative to current […]

AbbVie preps filings after ABBV-951 tops oral Parkinson’s drugs in trial

October 29, 2021 Auto Bot 0

AbbVie has reported that a subcutaneous infusion of Parkinson’s disease candidate ABBV-951 was more effective than standard oral therapy in a phase 3 trial, paving […]

AbbVie Reports Results of ABBV-951 (foslevodopa/foscarbidopa) in P-III M15-736 Study for the Treatment of Advanced Parkinson’s Disease

October 29, 2021 Auto Bot 0

Shots: The P-III M15-736 Study evaluates the efficacy, safety & tolerability of ABBV-951 to levodopa/carbidopa in 130 adult patients with advanced PD across 80 sites […]